Introducing the tolerogenic macrophage therapy as an alternative approach to manage systemic lupus erythematosus: a case series
<p><strong>Introduction: </strong>Systemic Lupus Erythematosus (SLE) has been quite an enigma in medicine. The possibility of the host own defense mechanism attacking itself is still quite difficult to understand. Patients who suffer from this disease tend to have a problem in thei...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
DiscoverSys
2019-12-01
|
Series: | Bali Medical Journal |
Subjects: | |
Online Access: | https://balimedicaljournal.org/index.php/bmj/article/view/1621 |
id |
doaj-7fd168b09c0f4e9f969b429768a01292 |
---|---|
record_format |
Article |
spelling |
doaj-7fd168b09c0f4e9f969b429768a012922020-11-25T03:27:36ZengDiscoverSysBali Medical Journal2089-11802302-29142019-12-018372673210.15562/bmj.v8i3.1621711Introducing the tolerogenic macrophage therapy as an alternative approach to manage systemic lupus erythematosus: a case seriesTerawan Agus Putranto0Djoko Wibisono1Nyoto Widyo Astoro2Martina Lily Yana3Endra Tri Prabowo4Denny Irwansyah5Nurhadiyanta Nurhadiyanta6Yudo Rantung7Taruna Ikrar8Fred Fandrich9The Indonesia Army Medical Science Institute, Jakarta, Indonesia Department of Cellcure, RSPAD Gatot Soebroto, Jakarta, IndonesiaDepartment of Cellcure, RSPAD Gatot Soebroto, Jakarta, IndonesiaDepartment of Cellcure, RSPAD Gatot Soebroto, Jakarta, IndonesiaDepartment of Cellcure, RSPAD Gatot Soebroto, Jakarta, IndonesiaDepartment of Cellcure, RSPAD Gatot Soebroto, Jakarta, IndonesiaDepartment of Cellcure, RSPAD Gatot Soebroto, Jakarta, IndonesiaDepartment of Cellcure, RSPAD Gatot Soebroto, Jakarta, IndonesiaThe Indonesia Army Medical Science Institute, Jakarta, IndonesiaThe Indonesia Army Medical Science Institute, Jakarta, Indonesia Department of Cellcure, RSPAD Gatot Soebroto, Jakarta, Indonesia Pacific Health Sciences University, California, United States of AmericaDepartment of Cellcure, RSPAD Gatot Soebroto, Jakarta, Indonesia<p><strong>Introduction: </strong>Systemic Lupus Erythematosus (SLE) has been quite an enigma in medicine. The possibility of the host own defense mechanism attacking itself is still quite difficult to understand. Patients who suffer from this disease tend to have a problem in their qualities of life, especially as the majority affect female in their productive ages. Conservative therapy to manage this disease is widely developed and implemented. Since the known therapies have several side effects and limitation, a need to develop a new strategy that can re-establish the “tolerance” mechanism of our immune system is increasingly needed. Immunotherapy is already a promising field in the strategy against autoimmune cases. In our facility, we developed immunotherapy called ToM (Tolerogenic Macrophage) which similar to Mreg (Regulatory Macrophage) in order to utilise the “tolerance” ability of this immune apparatus.</p><p><strong>Case: </strong>In this study, we present 2 cases of female patients who suffer from SLE, which underwent ToM Therapy in our Cellcure facility in RSPAD Gatot Soebroto Jakarta-Indonesia. After the procedure the patient was monitored one month and one year. Clinical and control parameter such as ANA (IF) and ANA profile was examined again in both patients to measure the effect of this therapy<strong>. </strong>The ANA titer and the titer of specific antibodies such as dsDNA, Nucleosomes and Histones results show significant reduction, accompanied by the improvement of the symptoms.</p><p><strong>Conclusion: </strong>ToM Therapy seems to have a good efficacy as immunotherapy for SLE. Further study needed to establish this approach.</p>https://balimedicaljournal.org/index.php/bmj/article/view/1621tolerogenic macrophage, systemic lupus erythematosus, immunotherapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Terawan Agus Putranto Djoko Wibisono Nyoto Widyo Astoro Martina Lily Yana Endra Tri Prabowo Denny Irwansyah Nurhadiyanta Nurhadiyanta Yudo Rantung Taruna Ikrar Fred Fandrich |
spellingShingle |
Terawan Agus Putranto Djoko Wibisono Nyoto Widyo Astoro Martina Lily Yana Endra Tri Prabowo Denny Irwansyah Nurhadiyanta Nurhadiyanta Yudo Rantung Taruna Ikrar Fred Fandrich Introducing the tolerogenic macrophage therapy as an alternative approach to manage systemic lupus erythematosus: a case series Bali Medical Journal tolerogenic macrophage, systemic lupus erythematosus, immunotherapy |
author_facet |
Terawan Agus Putranto Djoko Wibisono Nyoto Widyo Astoro Martina Lily Yana Endra Tri Prabowo Denny Irwansyah Nurhadiyanta Nurhadiyanta Yudo Rantung Taruna Ikrar Fred Fandrich |
author_sort |
Terawan Agus Putranto |
title |
Introducing the tolerogenic macrophage therapy as an alternative approach to manage systemic lupus erythematosus: a case series |
title_short |
Introducing the tolerogenic macrophage therapy as an alternative approach to manage systemic lupus erythematosus: a case series |
title_full |
Introducing the tolerogenic macrophage therapy as an alternative approach to manage systemic lupus erythematosus: a case series |
title_fullStr |
Introducing the tolerogenic macrophage therapy as an alternative approach to manage systemic lupus erythematosus: a case series |
title_full_unstemmed |
Introducing the tolerogenic macrophage therapy as an alternative approach to manage systemic lupus erythematosus: a case series |
title_sort |
introducing the tolerogenic macrophage therapy as an alternative approach to manage systemic lupus erythematosus: a case series |
publisher |
DiscoverSys |
series |
Bali Medical Journal |
issn |
2089-1180 2302-2914 |
publishDate |
2019-12-01 |
description |
<p><strong>Introduction: </strong>Systemic Lupus Erythematosus (SLE) has been quite an enigma in medicine. The possibility of the host own defense mechanism attacking itself is still quite difficult to understand. Patients who suffer from this disease tend to have a problem in their qualities of life, especially as the majority affect female in their productive ages. Conservative therapy to manage this disease is widely developed and implemented. Since the known therapies have several side effects and limitation, a need to develop a new strategy that can re-establish the “tolerance” mechanism of our immune system is increasingly needed. Immunotherapy is already a promising field in the strategy against autoimmune cases. In our facility, we developed immunotherapy called ToM (Tolerogenic Macrophage) which similar to Mreg (Regulatory Macrophage) in order to utilise the “tolerance” ability of this immune apparatus.</p><p><strong>Case: </strong>In this study, we present 2 cases of female patients who suffer from SLE, which underwent ToM Therapy in our Cellcure facility in RSPAD Gatot Soebroto Jakarta-Indonesia. After the procedure the patient was monitored one month and one year. Clinical and control parameter such as ANA (IF) and ANA profile was examined again in both patients to measure the effect of this therapy<strong>. </strong>The ANA titer and the titer of specific antibodies such as dsDNA, Nucleosomes and Histones results show significant reduction, accompanied by the improvement of the symptoms.</p><p><strong>Conclusion: </strong>ToM Therapy seems to have a good efficacy as immunotherapy for SLE. Further study needed to establish this approach.</p> |
topic |
tolerogenic macrophage, systemic lupus erythematosus, immunotherapy |
url |
https://balimedicaljournal.org/index.php/bmj/article/view/1621 |
work_keys_str_mv |
AT terawanagusputranto introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries AT djokowibisono introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries AT nyotowidyoastoro introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries AT martinalilyyana introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries AT endratriprabowo introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries AT dennyirwansyah introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries AT nurhadiyantanurhadiyanta introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries AT yudorantung introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries AT tarunaikrar introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries AT fredfandrich introducingthetolerogenicmacrophagetherapyasanalternativeapproachtomanagesystemiclupuserythematosusacaseseries |
_version_ |
1724588124890202112 |